Our Science – Gulley Website

James L. Gulley, M.D., Ph.D.

Selected Publications

1) Figg WD, Hussain MH, Gulley JL, Arlen PM, Aragon-Ching JB, Petrylak DP, Higano CS, Steinberg SM, Chatta GS, Parnes H, Wright JJ, Sartor O, Dahut WL.
A double-blind randomized crossover study of oral thalidomide versus placebo for androgen dependent prostate cancer treated with intermittent androgen ablation.
J. Urol. 181: 1104-13; discussion 1113, 2009. [Journal]

2) Ferrara TA, Hodge JW, Gulley JL.
Combining radiation and immunotherapy for synergistic antitumor therapy.
Curr. Opin. Mol. Ther. 11: 37-42, 2009. [Journal]

3) Aragon-Ching JB, Jain L, Gulley JL, Arlen PM, Wright JJ, Steinberg SM, Draper D, Venitz J, Jones E, Chen CC, Figg WD, Dahut WL.
Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer.
BJU Int. 103: 1636-40, 2009. [Journal]

4) Aragon-Ching JB, Ning YM, Chen CC, Latham L, Guadagnini JP, Gulley JL, Arlen PM, Wright JJ, Parnes H, Figg WD, Dahut WL.
Higher incidence of Osteonecrosis of the Jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents.
Cancer Invest. 27: 221-6, 2009. [Journal]

5) Cereda V, Poole DJ, Palena C, Das S, Bera TK, Remondo C, Gulley JL, Arlen PM, Yokokawa J, Pastan I, Schlom J, Tsang KY.
New gene expressed in prostate: a potential target for T cell-mediated prostate cancer immunotherapy.
Cancer Immunol. Immunother. 2009. [Journal]

6) Dahut WL, Aragon-Ching JB, Woo S, Tohnya TM, Gulley JL, Arlen PM, Wright JJ, Ventiz J, Figg WD.
Phase I study of oral lenalidomide in patients with refractory metastatic cancer.
Journal of clinical pharmacology. 49: 650-60, 2009. [Journal]

7) Arlen PM, Mohebtash M, Madan RA, Gulley JL.
Promising novel immunotherapies and combinations for prostate cancer.
Future oncology (London, England). 5: 187-96, 2009. [Journal]

8) Madan RA, Arlen PM, Mohebtash M, Hodge JW, Gulley JL.
Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer.
Expert opinion on investigational drugs. 18: 1001-11, 2009. [Journal]

9) Dahut WL, Scripture C, Posadas E, Jain L, Gulley JL, Arlen PM, Wright JJ, Yu Y, Cao L, Steinberg SM, Aragon-Ching JB, Venitz J, Jones E, Chen CC, Figg WD.
A phase II clinical trial of sorafenib in androgen-independent prostate cancer.
Clin. Cancer Res. 14: 209-14, 2008. [Journal]

10) Sharifi N, Hamada A, Sissung T, Danesi R, Venzon D, Baum C, Gulley JL, Price DK, Dahut WL, Figg WD.
A polymorphism in a transporter of testosterone is a determinant of androgen independence in prostate cancer.
BJU Int. 2008. [Journal]

Click Here to View Expanded Bibliography.

This page was last updated on 7/27/2009.